Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

NCT02645149 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

216

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Standard therapy or clinical trial
DRUG: Matched targeted therapy
DRUG: Trametinib and / or supportive care
DRUG: CDK4/6 and MEK inhibitor
DRUG: Compassionate Access Targeted Therapy

Sponsor

Melanoma Institute Australia

Collaborators

[object Object]